Phuoc Tran, MD, PhD
Stereotactic ablative radiation (SABR) reduced disease progression compared with observation in patients with oligometastatic prostate cancer, according to findings from the phase II ORIOLE study published in JAMA Oncology
Tran and his team are also exploring SABR in the RAVENS trial (NCT04037358), which is combining SABR with radium-223 (Xofigo) in patients with oligometastatic prostate cancer.
- Intense Form of Radiation Slows Disease Progression in Some Men with Prostate Cancer That Has Spread. Published online March 26, 2020. https://bit.ly/3bA0xBN. Accessed March 27, 2020.
- Phillips R, Shi WY; Deek M, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial [published online March 26, 2020]. JAMA Oncol. doi:10.1001/jamaoncol.2020.0147
... to read the full story